Full Press Release Details
dupixent dupilumab data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases.
REGN
dupixent dupilumab data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases
Key Takeaway: dupixent dupilumab data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases